Radiomic signatures associated with tumor immune heterogeneity predict survival in locally recurrent nasopharyngeal carcinoma.

Autor:	Lin DF; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangzhou, China.; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Li HL; School of Engineering Medicine, Beihang University, Beijing, China.; Chinese Academy of Sciences Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China., Liu T; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangzhou, China.; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.; Department of Breast Surgery, Breast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Lv XF; State Key Laboratory of Oncology in South China, Guangzhou, China.; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.; Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China., Xie CM; State Key Laboratory of Oncology in South China, Guangzhou, China.; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.; Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China., Ou XM; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Guan J; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Zhang Y; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Yan WB; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., He ML; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Mao MY; Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Zhao X; Chinese Academy of Sciences Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China., Zhong LZ; Chinese Academy of Sciences Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China., Chen WH; Department of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, China., Chen QY; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangzhou, China.; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Mai HQ; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangzhou, China.; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Peng RJ; State Key Laboratory of Oncology in South China, Guangzhou, China.; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.; Department of VIP Inpatient, Sun Yat-sen University Cancer Center, Guangzhou, China., Tian J; School of Engineering Medicine, Beihang University, Beijing, China.; Chinese Academy of Sciences Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.; National Key Laboratory of Kidney Diseases, Beijing, China., Tang LQ; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Guangzhou, China.; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China., Dong D; Chinese Academy of Sciences Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China.; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China.; National Key Laboratory of Kidney Diseases, Beijing, China.
Jazyk:	angličtina
Zdroj:	Journal of the National Cancer Institute [J Natl Cancer Inst] 2024 Aug 01; Vol. 116 (8), pp. 1294-1302.
DOI:	10.1093/jnci/djae081
Abstrakt:	Background: The prognostic value of traditional clinical indicators for locally recurrent nasopharyngeal carcinoma is limited because of their inability to reflect intratumor heterogeneity. We aimed to develop a radiomic signature to reveal tumor immune heterogeneity and predict survival in locally recurrent nasopharyngeal carcinoma. Methods: This multicenter, retrospective study included 921 patients with locally recurrent nasopharyngeal carcinoma. A machine learning signature and nomogram based on pretreatment magnetic resonance imaging features were developed for predicting overall survival in a training cohort and validated in 2 independent cohorts. A clinical nomogram and an integrated nomogram were constructed for comparison. Nomogram performance was evaluated by concordance index and receiver operating characteristic curve analysis. Accordingly, patients were classified into risk groups. The biological characteristics and immune infiltration of the signature were explored by RNA-sequencing analysis. Results: The machine learning signature and nomogram demonstrated comparable prognostic ability to a clinical nomogram, achieving concordance indexes of 0.729, 0.718, and 0.731 in the training, internal, and external validation cohorts, respectively. Integration of the signature and clinical variables statistically improved the predictive performance. The proposed signature effectively distinguished patients between risk groups with statistically distinct overall survival rates. Subgroup analysis indicated the recommendation of local salvage treatments for low-risk patients. Exploratory RNA-sequencing analysis revealed differences in interferon response and lymphocyte infiltration between risk groups. Conclusions: A magnetic resonance imaging-based radiomic signature predicted overall survival more accurately. The proposed signature associated with tumor immune heterogeneity may serve as a valuable tool to facilitate prognostic stratification and guide individualized management for locally recurrent nasopharyngeal carcinoma patients. (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu